*Gulp* Much to the relief of the needle-shy, the FDA has just approved a second oral GLP-1 drug, following the release of the semaglutide Wegovy pill in January. But this new tablet, from pharma giant ...

Learn how new oral GLP-1 weight loss pills work, how they compare with injections, and how next-gen “small molecule” drugs ...

BOULDER, Colo., March 31, 2026 /PRNewswire/ -- Ambrosia Biosciences Inc. ("Ambrosia") today announced a $100 million oversubscribed Series B financing.

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule GLP-1 ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC30 SQ ...

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...